Insulin Infusion Pumps Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Insulin Infusion Pumps Market by product type ( Closed loop pumps, Open loop pumps, Others), diabetes type (Type -1 diabetes, Type-2 diabetes), end user (Hospital pharmacies, Online pharmacies, Others) Geography.

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The Global Insulin Infusion Pumps Market size was estimated at USD 12.2 Bn in 2021, growing at a CAGR of 8.9% during the forecast period 2021-2027. Insulin infusion pumps are the devices which are used to administer insulin in diabetes mellitus patients. Insulin infusion pumps administer the accurate dose of insulin into the body with less pain. Insulin pumps are working as alternative systems for insulin pen and daily insulin injection. Scheduling of mealtime is not required with the using of insulin infusion pumps. Insulin infusion pumps contain a pump, reservoir, tubing system, and disposable infusion set with a cannula for the subcutaneous insertion. These devices reduce the number of insulin daily injections with syringe or pen. Insulin Infusion Pumps Market is growing at a significant CAGR owing to increase in the technological advancements in the insulin devices. Increase in the prevalence of diabetes fuels the growth of insulin pumps market. According to the International Diabetes Federation (IDF), 7 Mn people are added every year to the pool of 246 million diabetics, which is projected to increase approximately 438 Mn by 2030. Patent approvals, product launchings, product approvals, innovation of novel products, and acquisitions are the strategies followed by the companies for strengthening position in the insulin infusion pumps market. For instance, Tandem Diabetes Care, Inc. filled a U.S. patent for the medical infusion pump with remote bolus feature. Moreover, in September 2016, Medtronic Minimed, Inc. received FDA approval for insulin infusion pump 670G system with continuous glucose monitoring system.


Insulin Infusion Pumps Market

MARKET SUMMARY
-
8.8% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 8.8%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Insulin Infusion Pumps Market

 

  • The report on global Insulin Infusion Pumps Market gives historical, current, and future market sizes (US$ Mn) on the basis of
    product type, diabetes type, end user and region.
  • global Insulin Infusion Pumps Market report gives comprehensive outlook across the region with special emphasis on key regions
    such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • In August 2017, Tandem Diabetes Care, Inc. launched t: slim X2 insulin pump with continuous glucose monitoring feature
  • In December 2016, Animas Corporation received Health Canada’s authorization and FDA approval for OneTouch Vibe Plus insulin pump with continuous glucose monitoring (CGM) system
Market Key Players
  • Insulet Corporation (U.S.)
  • Ypsomed (Switzerland)
  • Tandem Diabetes Care, Inc. (U.S.)
  • Animas Corporation (U.S.)
  • Cellnovo Group SA (France)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • Smiths Medical (U.S.)
  • Sooil developments Co., Ltd. (South Korea)
Drivers And Restraints

Insulin Infusion Pumps Market

Increase in the prevalence of diabetes, a rise in geriatric population, technological advancements of the devices, and ease of administration of insulin with infusion pumps are fuelling the insulin infusion pumps market. Furthermore, increase in the preference for home-based insulin therapy, accuracy in releasing of insulin dose, flexibility in meal scheduling and marketing activities by the market players are anticipated to propel the insulin infusion pumps market over the forecast period. However, product recalls, the high cost of devices, lack of awareness about insulin infusion pumps, and lack of reimbursement policies for insulin devices are the factors impeding the growth of Insulin Infusion Pumps Market.


North-America got significant share

Insulin Infusion Pumps Market

Geographically, the insulinInfusion Pumps Market is segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Increase in the prevalence of diabetes in North America majorly in U.S. (According to American Diabetes Association, the prevalence of diabetes in 2015 is 30.3 Mn or 9.4% in U.S.), a rise in the healthcare expenditure and technological advancements in insulin infusion pumps are driving the insulin pumps market in North America region. Europe insulin infusion pumps market is expected to fuel at significant rate over the forecast years owing to upsurge in the diabetes population majorly in Germany, Russia, and U.K (according to Diabetes UK 2016, about 3.6 Mn people are suffering from diabetes in the U.K. region), and adoption of modern technologies in Europe region. Moreover, Asia Pacific exhibiting significant growth which is attributed to increase in diabetes population majorly in India and China (according to the International Diabetes Federation, in 2015, in China around 96.2 million diabetic patients and in India 66.8 million patients are suffering from diabetes.), rise in healthcare expenditure, and adoption of novel insulin delivery device in Asia Pacific region are the factors expected to bolster the Insulin Infusion Pumps Market over the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, and forecast from 2021-2027
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments, and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Segmentation

Insulin Infusion Pumps Market


Location

GEOGRAPHY


Report

Table Of Content


Report

Company Profile

  • Insulet Corporation (U.S.)
  • Ypsomed (Switzerland)
  • Tandem Diabetes Care, Inc. (U.S.)
  • Animas Corporation (U.S.)
  • Cellnovo Group SA (France)
  • F. Hoffmann La Roche Ltd. (Switzerland)
  • Smiths Medical (U.S.)
  • Sooil developments Co., Ltd. (South Korea)

Description

The Global Insulin Infusion Pumps Market size was estimated at USD 12.2 Bn in 2021, growing at a CAGR of 8.9% during the forecast period 2021-2027. Insulin infusion pumps are the devices which are used to administer insulin in diabetes mellitus patients. Insulin infusion pumps administer the accurate dose of insulin into the body with less pain. Insulin pumps are working as alternative systems for insulin pen and daily insulin injection. Scheduling of mealtime is not required with the using of insulin infusion pumps. Insulin infusion pumps contain a pump, reservoir, tubing system, and disposable infusion set with a cannula for the subcutaneous insertion. These devices reduce the number of insulin daily injections with syringe or pen. Insulin Infusion Pumps Market is growing at a significant CAGR owing to increase in the technological advancements in the insulin devices. Increase in the prevalence of diabetes fuels the growth of insulin pumps market. According to the International Diabetes Federation (IDF), 7 Mn people are added every year to the pool of 246 million diabetics, which is projected to increase approximately 438 Mn by 2030. Patent approvals, product launchings, product approvals, innovation of novel products, and acquisitions are the strategies followed by the companies for strengthening position in the insulin infusion pumps market. For instance, Tandem Diabetes Care, Inc. filled a U.S. patent for the medical infusion pump with remote bolus feature. Moreover, in September 2016, Medtronic Minimed, Inc. received FDA approval for insulin infusion pump 670G system with continuous glucose monitoring system.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX